Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Atossa Genetics Inc (ATOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,724
  • Shares Outstanding, K 9,125
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,400 K
  • 60-Month Beta 3.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -2.90
  • Growth Rate Est. (year over year) +34,548.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.30 +13.04%
on 05/15/19
4.26 -38.97%
on 04/25/19
-0.88 (-25.29%)
since 04/24/19
3-Month
1.36 +91.18%
on 03/05/19
7.39 -64.82%
on 03/14/19
+1.08 (+71.05%)
since 02/22/19
52-Week
0.80 +225.00%
on 12/26/18
7.39 -64.82%
on 03/14/19
-0.60 (-18.75%)
since 05/24/18

Most Recent Stories

More News
Atossa Genetics Announces First Quarter 2019 Financial Results and Provides Company Update

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial...

ATOS : 2.60 (-0.38%)
Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced that today Steven...

ATOS : 2.60 (-0.38%)
Thinking about buying stock in Aurora Cannabis Inc., Akari Therapeutics, Atossa Genetics Inc., Boeing Co., or Reebonz Holding Ltd.?

InvestorsObserver issues critical PriceWatch Alerts for ACB, AKTX, ATOS, BA, and RBZ.

AKTX : 2.30 (-1.71%)
ACBFF : 8.6900 (-12.80%)
ATOS : 2.60 (-0.38%)
BA : 354.90 (+1.24%)
Atossa Genetics to Present at the 4th Annual Precision: Breast Cancer World R&D Summit April 25, 2019

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Steven...

ATOS : 2.60 (-0.38%)
New Research Coverage Highlights Thermon Group, Apogee Enterprises, National Research, Gulf Resources, Atossa Genetics, and Broadwind Energy -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Thermon Group Holdings, Inc....

GURE : 1.15 (unch)
BWEN : 1.90 (+4.94%)
NRCIA : 33.55 (+1.51%)
APOG : 39.15 (+0.88%)
ATOS : 2.60 (-0.38%)
NRC : 51.29 (-0.41%)
THR : 23.58 (-0.88%)
Biotechs Strive to Provide Patients With More Affordable Treatment Options

The American Cancer Society estimated that in 1991, cancer deaths peaked at 215 deaths per 100,000 persons. As of 2014, the rate dropped significantly to just 161 deaths per 100,000 persons, representing...

AGEN : 2.86 (-3.38%)
OMED : 0.93 (+4.49%)
ATOS : 2.60 (-0.38%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0102 (-19.69%)
SNSS : 0.94 (-10.48%)
Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced year...

ATOS : 2.60 (-0.38%)
Atossa Genetics Announces Institutional Review Board Approval of Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that...

ATOS : 2.60 (-0.38%)
Estimated Revenues Continue to Rise for U.S. and Global Medical Device Markets

The U.S. medical device industry has seen its revenues continue to increase and it is poised is to become the global leader of this expanding market. It seems as though each new projection breaks through...

DERM : 9.95 (+2.37%)
ATOS : 2.60 (-0.38%)
BPTH : 14.54 (-0.82%)
AVGR : 0.46 (-3.19%)
SOLY : 5.73 (+4.95%)
Atossa Genetics Announces Receipt of $10 Million

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that...

ATOS : 2.60 (-0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ATOS with:

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

2nd Resistance Point 2.68
1st Resistance Point 2.64
Last Price 2.60
1st Support Level 2.54
2nd Support Level 2.48

See More

52-Week High 7.39
Fibonacci 61.8% 4.87
Fibonacci 50% 4.09
Fibonacci 38.2% 3.32
Last Price 2.60
52-Week Low 0.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar